Cognition Therapeutics Inc. is a drug discovery and development company located in Pittsburgh, Pennsylvania. Founded in 2007, the company uses proprietary biology and chemistry platforms to discover novel drug targets and disease modifying therapies for disorders of the central nervous system.
We are seeking a Neuroscientist/Cell Biologist at our headquarters in Pittsburgh, PA. We offer a competitive salary and excellent benefits.
What You’ll Do
The candidate will be a key contributor to a scientific research team developing cutting edge assay methodology for neurodegenerative protein targets. Responsibilities include evaluation of new targets for neurodegenerative diseases and clinical biomarkers, statistical data analysis, studies of compound mechanism of action, and assay development. Candidate will work with internal team members, contribute to scientific publications and NIH grant applications, and academic collaborators and travel to scientific meetings to present company results.
What You’ll Bring
PhD in Neuroscience or related field, plus 5-10 years experience (industry experience a requirement)
Background in cell biology/ pharmacology/biochemistry of target proteins implicated in neurodegeneration
Ability to critically analyze and interpret data, define realistic timelines for studies and meet delivery deadlines
Technical expertise in neurobiological techniques (e.g., primary culture of neurons, imaging techniques, protein biochemistry, design and interpretation of behavioral studies)
Excellent teamwork, communication, and analytical skills
Authorized to work in the United States
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. is a privately held biopharmaceutical company focused on the development of a pipeline of disease-modifying small molecule drug candidates that normalize the impaired protein trafficking pathways that are the root cause of many CNS disorders. By so doing, Cognition’s drug candidates aim to preserve brain health and function. Cognition’s lead candidate, Elayta (CT1812), is a proprietary first-in-class, orally dosed and highly brain penetrant small molecule. Elayta was designed to normalize the protein trafficking pathways responsible for synaptic plasticity, which are compromised when the oligomeric form of the A? protein binds to neurons. This binding triggers a neurotoxic cascade that disrupts normal protein trafficking and leads to further damaging downstream effects. Elayta displaces oligomers from their target receptor, removing them from brain cell synapses and clearing them out of the brain into the cerebrospinal fluid (CSF). Additional information about Cognition may be found online at http://www.cogrx.com.